Oncology
Hematological Malignancies
7
Pipeline Programs↗
46
Active Trials↗
38
Companies Involved↗
Hematological Malignancies is an early-stage landscape with 7 programs across 38 companies. The most active players are Johnson & Johnson, Daiichi Sankyo, AstraZeneca. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 1
No programs
Approved
No programs
Analysis
Modality Breakdown
7programs
Small molecule457%
Monoclonal antibody229%
Cell therapy114%
Modality classified for 100% of 7 pipeline programs.
Analysis
Trial Status
129
clinical trials
Completed46 · 36%
Recruiting33 · 26%
Terminated18 · 14%
Unknown status14 · 11%
Not yet recruiting8 · 6%
Active, not recruiting5 · 4%
Other5 · 4%
Clinical Trials
Trial Activity
129 trials
Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies
Recruiting·—·Phase 2·NCT06462248·20 enrolled
Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies
Recruiting·—·N/A·NCT05536154·68 enrolled
Page 1 of 9
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)